Tirzepatide NHS criteria: who qualifies, and what if you don't?

What does NICE actually say about who qualifies on the NHS?

NICE's appraisal of tirzepatide (TA1026, published in December 2024 and updated in September 2025) recommends it for adults with a BMI of 35 or above who also have at least one weight-related comorbidity from a defined list: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, the thresholds drop by 2.5 kg/m².

Crucially, NICE's recommendation did not mean the medicine became available to everyone who met those criteria on the same day. NHS England set up a phased rollout because demand is enormous and specialist services need time to prepare. The guidance also says treatment should be reviewed if someone loses less than 5% of their body weight after six months at the highest tolerated dose. That review triggers a conversation, not an automatic stop.

If you want the full detail of how those recommendations translate into NHS access, the NHS criteria for Mounjaro page sets it out condition by condition.

Which NHS cohorts are open right now, and when do the next ones begin?

The phased rollout follows a staged schedule. The first cohort opened in June 2025 for people with a BMI of 40 or above who have four or more of the five qualifying conditions. That is a high bar deliberately, reaching those with the most complex clinical picture first.

The second cohort activated on 23 June 2026, extending access to people with a BMI between 35 and 39.9 who also have four or more qualifying conditions. From around March 2027, the threshold for the number of conditions is expected to drop to three, still at a BMI of 40 or above. Each step widens the net, but the pace is measured.

From 1 April 2026, some GP practices can prescribe tirzepatide directly under the updated GP contract, which is genuinely useful for patients who would otherwise need a hospital referral. Participation is optional for practices, though, so the picture varies by surgery and by area. You might find your GP is now able to help; you might find yours is not. For a clearer picture of how 2025 and 2026 phases compare, the 2025 NHS Mounjaro criteria page and the 2026 update sit alongside each other for comparison.

What happens if you meet the licensed criteria but not the NHS cohort thresholds?

This is the situation most people are actually in. Someone with a BMI of 32, hypertension, and high cholesterol is clinically eligible for tirzepatide under the terms of its UK licence (it is approved for adults with a BMI of 27 or above when a weight-related condition is present) but they fall outside every NHS cohort that is currently open.

A private prescription from a GPhC-registered online pharmacy is the lawful route in that situation. Private treatment is also the realistic option for people who technically qualify for NHS access but are looking at a long wait through a specialist weight management service. Many people simply cannot put their health on hold for months or years.

The cost involved in going private is worth understanding clearly. Tirzepatide's list price rose sharply from September 2025 after Eli Lilly revised UK pricing, with some doses now typically reported in the £149–£375 per month range depending on dose and provider. How those figures break down (and what a legitimate price should include) is explained on the Mounjaro prices page. The short version: any honest price covers the consultation, the prescription, and the clinical review; providers who strip those out to show a lower headline figure are not showing you the real cost.

How does a private clinical assessment for tirzepatide actually work?

The process is straightforward. A consultation for tirzepatide at a regulated online pharmacy involves answering health questions that a prescriber reviews personally. At nume, that review is done by a GPhC-registered Independent Prescriber, a real clinician reading your answers, not a system auto-approving them. Photo-ID checks and live weight verification by video are part of the process, because supplying a prescription-only medicine without proper identity and clinical checks is not acceptable practice.

If you order before noon on a working day and the prescriber approves your treatment as clinically suitable, dispatch happens the same day. The pen arrives the next working day via DPD in plain, unbranded packaging. There are no subscriptions; every repeat order goes through a fresh clinical review before anything is sent. If you want to see what the full treatment range looks like before starting, the treatment options page covers everything in one place. And if you have specific questions about the clinical team behind these assessments, our prescribers' profile page is there to read.

Treatment does not start at a therapeutic dose. The first pen is 2.5mg, which exists to let your system adjust before any titration begins. The prescriber manages that progression. If you're unsure whether tirzepatide is right for your situation, you can buy tirzepatide through our pharmacy once a prescriber has confirmed it is suitable for you, and starting with a general overview of weight-loss treatment options might help you frame the question before you consult.